Emerging human studies provide encouraging translational support, showing that luteolin, administered primarily as ultramicronized PEA-luteolin, reduces key inflammatory cytokines (IL-6, IL-1, TNF-), mast-cell mediators, and oxidative stress biomarkers (Cordaro et al., 2020
Inappropriate ingredients Some pharmacies sell compounded semaglutide in combination with other ingredients that have not been studied in clinical trials for their safety such as the peptide BPC-157
Research Novo Nordisk's savings program for details
The surge in people using these medicines outside of carefully controlled studies, and chatting about it online, is increasing our understanding of the drugs side effects and how they tend to be used in real life, beyond doctors close supervision
This work received funding from Nurture, Cipla Ltd